Canada · Delayed Price · Currency is CAD HLS Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Cardiovascular net sales surged 25% year-over-year, driven by Vascepa and a robust NILEMDO launch, while CLOZARIL's Canadian patient base grew for five months. Cash flow and balance sheet strength enabled share buybacks and ongoing debt reduction. 2026 guidance is reaffirmed.
-
The meeting addressed financial statements, elected Directors, reappointed the Auditor, and approved the Long-Term Incentive Plan, with all resolutions passing. Voting was conducted virtually, and results will be disclosed on SEDAR+ and via press release.
-
Q1 2026 saw 2% revenue growth, strong Vascepa sales, and a successful NILEMDO launch with rapid private payer coverage. Operational improvements boosted cash flow and reduced net debt, while guidance for 2026 was reaffirmed and margin expansion is expected in the second half.
-
Operational improvements and a strengthened balance sheet have set the stage for accelerated growth, with new cardiovascular launches like Nilemdo and NEXLIZET targeting significant unmet needs. Early market access wins and a robust product pipeline support a positive outlook through 2027.
Fiscal Year 2025
-
Revenue for 2025 was $55.5M with 18% Adjusted EBITDA growth and strong cash flow. Vascepa demand rose 23%, NILEMDO launched in Canada, and net debt fell 23%. 2026 guidance is for modest revenue growth, with major expansion expected from NILEMDO and NEXLIZET launches.
-
Adjusted EBITDA rose 19% in Q3 and 25% year-to-date, driven by operational improvements and cost discipline. Pasipa and Clozaril showed mixed performance, with strong growth in Western Canada and U.S. stability, while new cardiovascular launches are set to drive future growth.
-
Q2 2025 saw revenue of $14.2M and adjusted EBITDA up 21%, with strong cash flow growth and reduced debt. Vascepa and Clozaril showed solid performance, and preparations for Nexletol/Nexlizet launch are on track, with minimal incremental costs expected.
-
The meeting covered financial statements, director elections, and auditor reappointment, all of which passed with shareholder support. No questions were raised, and risk factors were referenced. Q2 results are expected in early August.
-
Q1 2025 saw revenue and adjusted EBITDA growth, driven by strong Vascepa and Clozaril performance, operational efficiencies, and the in-licensing of Nexletol and Nexlizet. Guidance for 2025 remains unchanged, with no significant incremental spend expected for new product launches.
Fiscal Year 2024
-
2024 saw strong core product growth, major cost reductions, and significant debt repayment, positioning the company for 2025 EBITDA growth of 17–23%. Vascepa and Clozaril both contributed positively, with Vascepa expected to be profitable for the full year in 2025.
-
Q3 saw strong Canadian growth for Vascepa and Clozaril, with operating expenses and debt significantly reduced. Vascepa is set to contribute positively to Adjusted EBITDA in Q4, while 2024 guidance was adjusted for U.S. Clozaril and FX impacts.
-
Significant leadership and operational changes have refocused the business on its core product portfolio, driving growth in both psychiatric and cardiovascular markets. Financial performance is improving through cost reductions, debt repayment, and strong product demand, positioning the company for future expansion and profitability.
-
Q2 saw 9% year-over-year growth in marketed product revenue, double-digit sales increases for Clozaril and Vascepa in Canada, and a 13% reduction in operating expenses. The Xenpozyme royalty sale enabled $14 million in debt repayment, strengthening the balance sheet.
-
The meeting covered financial statements, elected eight directors, and reappointed the auditor, with all motions passing. Virtual procedures ensured secure voting and Q&A, and risks related to forward-looking statements were highlighted.